![(+)-(3r,5s), Tert-Butyl 7-[4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methyl-N-Methylsulphonylamino)-Pyrimidin-5-Yl]-3,5 -Dihydroxy-6(E)-Heptenate (R1.5 los yog T-Butyl-Rosuvastatin) CAS: 355806-00-7 Cov duab tshwj xeeb](http://cdn.globalso.com/xdbiochems/白色粉末1133.jpg)
![(+)-(3r,5s), Tert-Butyl 7-[4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methyl-N-Methylsulphonylamino)-Pyrimidin-5-Yl]-3,5 -Dihydroxy-6(E)-Heptenate (R1.5 los yog T-Butyl-Rosuvastatin) CAS: 355806-00-7](http://cdn.globalso.com/xdbiochems/粉末245.jpg)
(+)-(3r,5s), Tert-Butyl 7-[4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methyl-N-Methylsulphonylamino)-Pyrimidin-5-Yl]-3,5 -Dihydroxy-6(E)-Heptenate (R1.5 los yog T-Butyl-Rosuvastatin) CAS: 355806-00-7
| Catalog Number | xwm 93420 |
| Khoom npe | (+)-(3r,5s), Tert-Butyl 7-[4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methyl-N-Methylsulphonylamino)-Pyrimidin-5-Yl]-3,5 -Dihydroxy-6(E)-Heptenate (R1.5 los yog T-Butyl-Rosuvastatin) |
| CAS | 355806-00-7 |
| Molecular Formula | C26H36FN3O6S |
| Molecular Luj | 537.64 ib |
| Cov ntaub ntawv khaws cia | Ambient |
Khoom Specification
| Qhov tshwm sim | Dawb hmoov |
| Assay | 99% min |
(+)-(3R,5S), tert-Butyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-pyrimidin-5-yl]-3,5 -dihydroxy-6(E)-heptenate, tseem hu ua R1.5 los yog tert-butyl-rosuvastatin, yog ib qho tshuaj sib xyaw nrog cov kev siv hauv kev lag luam tshuaj.Rosuvastatin yog cov tshuaj zoo-paub cov roj cholesterol uas koom nrog hauv chav kawm. ntawm cov tshuaj hu ua statins.Nws ua haujlwm los ntawm inhibiting ib qho enzyme hu ua HMG-CoA reductase, uas koom nrog hauv kev tsim cov roj cholesterol hauv lub cev.R1.5 yog ib qho derivative ntawm rosuvastatin uas muaj cov pab pawg tert-butyl txuas nrog rau cov molecule, muab cov khoom ntxiv thiab cov txiaj ntsig zoo.Ib daim ntawv thov ntawm R1.5 yog cov khoom siv tshuaj rau kev kho mob hyperlipidemia thiab tiv thaiv kab mob plawv.Zoo li rosuvastatin, R1.5 tuaj yeem siv los txo qis LDL cholesterol, tseem hu ua "phem" cholesterol, thiab triglycerides hauv cov ntshav.Cov tshuaj no tuaj yeem ua kom pom cov tshuaj pharmacokinetic zoo dua, xws li nce bioavailability lossis txhim khu kev ruaj ntseg, piv rau niam txiv tshuaj.Tsis tas li ntawd, pawg tert-butyl tuaj yeem ua rau cov khoom sib xyaw solubility thiab kev tsim ntau yam, ua rau nws tsim nyog rau ntau lub tshuab xa tshuaj.Lwm qhov kev siv ntawm R1.5 yog nyob rau hauv kev txhim kho cov tshuaj los yog lub hom phiaj xa tshuaj.Cov pab pawg tert-butyl tuaj yeem ua raws li pab pawg tiv thaiv, tso cai rau kev tso tawm ntawm rosuvastatin hauv cov ntaub so ntswg lossis cov kabmob, xws li lub siab.Lub tswv yim no tuaj yeem txhim kho cov tshuaj ua tau zoo thiab txo qis cov kev mob tshwm sim los ntawm kev ua kom nws cov concentration ntawm lub hom phiaj thaum txo qhov cuam tshuam rau cov ntaub so ntswg uas tsis yog lub hom phiaj. Tsis tas li ntawd, R1.5 tuaj yeem ua cov cuab yeej tseem ceeb rau cov kws kho mob hauv kev tshawb nrhiav tshuaj thiab kev loj hlob.Lub complex qauv muab lub platform rau kev hloov kho ntxiv thiab derivatizations.Cov kws tshawb fawb tuaj yeem siv R1.5 los ua ib qho kev sib xyaw ua ke los tshawb nrhiav cov qauv-kev sib raug zoo thiab tsim cov analogs tshiab nrog kev txhawb zog, kev xaiv, lossis txhim kho cov kev kho mob.Cov kev tshawb fawb no yuav pab txhawb kev tsim cov tshuaj statins tshiab thiab zoo dua qub los yog lwm cov tshuaj txo cov roj cholesterol.Nyob rau hauv xaus, (+)-(3R,5S), tert-Butyl 7-[4-(4-fluorophenyl)-6-isopropyl -2-(N-methyl-N-methylsulphonylamino)-pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenate (R1.5 los yog tert-butyl-rosuvastatin) tuav cov lus cog tseg raws li cov tshuaj sib xyaw rau kev kho mob ntawm hyperlipidemia thiab kab mob plawv.Nws cov qauv tshwj xeeb, ua ke nrog cov pab pawg tert-butyl, tuaj yeem muab cov txiaj ntsig zoo xws li kev txhim kho pharmacokinetics, kev xa cov tshuaj, thiab lub sijhawm rau kev txhim kho tshuaj ntxiv.Kev tshawb fawb ntxiv thiab kev txhim kho yog xav tau los tshawb nrhiav qhov peev xwm ntawm R1.5 hauv kev lag luam tshuaj.
